EIS - ETF AI Analysis
Top Page
iShares MSCI Israel ETF (EIS)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains so far this year, showing resilience despite recent short-term volatility.
Leading Holdings with Strong Momentum
Several major positions, such as Tower, Elbit Systems, Nova, Phoenix, and Enlight Renewable Energy, have shown strong year-to-date performance, helping support the fund’s overall returns.
Focused Exposure to Israel with Some U.S. Balance
The fund is primarily invested in Israeli companies while still holding a meaningful U.S. allocation, giving investors targeted country exposure with a bit of geographic diversification.
Negative Factors
High Country Concentration
With most assets in Israel, the ETF is heavily exposed to that single country’s economic, political, and currency risks.
Significant Weight in a Few Stocks
The top holdings, including large positions in Teva, Leumi, and Poalim, make up a big share of the portfolio, increasing the impact if any one of them struggles.
Relatively High Expense Ratio
The fund’s ongoing fee is on the higher side for an ETF, which can gradually reduce investors’ net returns over time.
EIS vs. SPDR S&P 500 ETF (SPY)
AUM885.60M
RegionMiddle East & Africa
Expense Ratio0.59%
Beta0.78
IssueriShares
Inception DateMar 26, 2008
Dividend Yield1.53%
Asset ClassEquity
Index TrackedMSCI Israel Capped Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume18,627
30 Day Avg. Volume72,849
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EIS Summary
EIS is the iShares MSCI Israel ETF, which follows the MSCI Israel Capped Index to give you broad exposure to the Israeli stock market. It holds a mix of companies across many sectors, including well-known names like Teva Pharmaceutical and Leumi bank. Investors might consider EIS to diversify beyond the U.S., tap into Israel’s technology and healthcare growth, and gain access to a different regional economy in a single investment. However, because it focuses heavily on one country, its price can move up or down sharply with changes in Israel’s market and regional politics.
How much will it cost me?The iShares MSCI Israel ETF (EIS) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is passively managed but focuses on a niche market, which can involve higher costs to track the index effectively.
What would affect this ETF?The iShares MSCI Israel ETF (EIS) could benefit from Israel's strong presence in technology and healthcare, sectors known for innovation and growth potential. However, challenges such as geopolitical tensions in the Middle East or changes in global interest rates affecting financial institutions could negatively impact the ETF's performance. Investors should also consider how broader economic conditions and regulatory changes in Israel might influence its top holdings, including major banks and tech companies.
EIS Top 10 Holdings
EIS is essentially a bet on Israel’s banks and tech innovators, with financials like Leumi, Poalim, and Phoenix quietly steering the ship as steady to rising performers. Defense contractor Elbit Systems has been another bright spot, adding some firepower to returns. On the flip side, Teva Pharmaceutical has been losing steam, and chip-related names like Tower and Nova have seen more mixed, sometimes lagging moves, adding volatility. Overall, this is a tightly focused, Israel-only play, leaning on domestic finance and high-tech to drive the story.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Teva Pharmaceutical | 10.54% | $94.61M | $42.99B | 102.28% | 63 Neutral | |
| Leumi | 9.02% | $80.93M | ₪111.11B | 26.01% | 80 Outperform | |
| Poalim | 8.12% | $72.88M | ₪100.28B | 26.74% | 79 Outperform | |
| Tower | 6.10% | $54.73M | ₪75.02B | 306.70% | ― | |
| Elbit Systems | 5.05% | $45.30M | ₪104.87B | 48.40% | 73 Outperform | |
| Discount | 3.38% | $30.29M | ₪41.59B | 10.33% | 75 Outperform | |
| Phoenix | 3.29% | $29.51M | ₪44.88B | 47.35% | 79 Outperform | |
| Mizrahi Tefahot | 2.94% | $26.42M | ₪60.30B | 13.12% | 80 Outperform | |
| Nova | 2.90% | $26.01M | ₪35.79B | 49.12% | ― | |
| Enlight Renewable Energy | 2.76% | $24.79M | $11.42B | 156.98% | 77 Outperform |
EIS Technical Analysis
Positive
―
Price Trends
120.90
Positive
124.84
Negative
119.44
Positive
Market Momentum
0.40
Negative
52.55
Neutral
29.87
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EIS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 121.63, equal to the 50-day MA of 120.90, and equal to the 200-day MA of 119.44, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 52.55 is Neutral, neither overbought nor oversold. The STOCH value of 29.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EIS.
EIS Peer Comparison
Comparison Results
Performance Comparison
EIS
iShares MSCI Israel ETF
122.74
29.65
31.85%
JHMD
John Hancock Multifactor Developed International ETF
―
―
―
VFMF
Vanguard U.S. Multifactor ETF
―
―
―
DMXF
iShares ESG Advanced MSCI EAFE ETF
―
―
―
HLAL
Wahed FTSE USA Shariah ETF
―
―
―
ISRA
VanEck Israel ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents